

DAFTAR PUSTAKA

1. Winkler EA. et al. Cerebral Edema in Traumatic brain injury. *Neurosurgery Clinics of North America*. Elsevier Inc 2016; 27(4): pp. 473–88. doi: 10.1016/j.nec.2016.05.008
2. Vos PE. Arrastia RD. *Traumatic brain injury*. 1st ed. Oxford: Wiley Blackwell; 2015. pp. 3.
3. Khan A, Prince M, Brayne C, Prina AM. Lifetime prevalence and factors associated with head injury among older people in low and middle income countries: a 10/66 study. *PLoS One* 10 2015: e0132229.
4. Sekeon SAS, Maja PS, Kembuan M. Executive function disorder in acute traumatic brain injuryin Manado, Indonesia. *Global Journal of Medicine and Public Health* 2015; 4(2). ISSN 2277-9604
5. Zeng J. et al. Emodin attenuates brain edema after traumatic brain injuryin rats, 2017;10(11):15213–20.
6. Michinaga S. and Koyama Y. Pathogenesis of brain edema and investigation into anti- dema drugs, *International Journal of Molecular Sciences* 2015;16(5): 9949–75. doi: 10.3390/ijms16059949.

7. Donkin JJ. and Vink R. Mechanisms of cerebral edema in traumatic brain injury: Therapeutic developments, *Current Opinion in Neurology* 2010; 23(3): 293–9.
doi: 10.1097/WCO.0b013e328337f451.
8. Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, Peng X, Beeram MR, Davis ML, Huang JH and Tharakan B. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. *PLoS One* 2016; 11: e01544
9. Mina M, Samaneh O, Mohammad JK, Ali J, and Hamid Y. Minocycline is more potent than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro. *Jundishapur J Nat Pharm Prod.* 2016 May; 11 (2):e27377.
10. Garrido M, A Zarzuelo. Minocycline: Far Beyond an Antibiotic. *Br J Pharmacol.* 2013 May; 169(2): 337–352. doi: 10.1111/bph.12139
11. Caprio RD, Lembo S, Costanzo LD, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: An in vitro study. *Hindawi Publishing Corporation* 2015: 1-2.
12. Nascimento GC, Rizzi E, Gerlach RF, Leite-Panissi CR. Expression of MMP-2 and MMP-9 in the rat trigeminal ganglion during the development of temporomandibular joint inflammation. *Braz J Med Biol Res* 2013; 46: 956-67.

13. Shen LC, Chen YK, Lin LM, Shaw SY. Anti-invasion and antitumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma-in vitro and in vivo studies. *Oral Oncol* 2010; 46: 178-84.
14. Saekhu M, et al. MMP-9, Brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline. *Med J Indones*, December 2016: 25(4): 221-6. eISSN: 2252-8083
15. Jia F, Pan Y, Mao Q, Liang Y, Jiang J. Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. *Journal of Neurotrauma*. June 2010. 27:1059–68. DOI: 10.1089=neu.2009.1067
16. Hayashia T. Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats. *Elsevier Brain research*. 2009:172-7. doi:10.1016/j.brainres.2009.05.040
17. Haddas O, et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. *PLoS ONE* 8(10): e76904. doi:10.1371/journal.pone.0076904
18. Prasetyo E, Islam AA, Hatta M, Widodo D, Pattelongi I. The Profile of MMP-9, MMP-9 mRNA Expression, -1562 C/T polymorphism and

outcome in high-risk traumatic brain injury: the effect of therapeutic mild hypothermia. *Neurologia medico-chirurgica Advance*. October 2017. doi: 10.2176/nmc.oa.2016-0322

19. Prativa S, Tim L, Hidenori S, Yu H, William R, Kamil D, et al. *Minocycline Improves Functional Outcomes, Memory Deficits, and Histopathology after Endovascular Perforation-Induced Subarachnoid Hemorrhage in Rats*. *J Neurotrauma*. 2011 Dec; 28(12): 2503–2512.
20. Moore AJ. Management of severe head injury. In: Newell DW, editor. *Neurosurgery*. London: Springer-Verlag; 2005. pp. 369-71. ISBN 1-85233-522-X
21. Webster KM. et al. Inflammation in epileptogenesis after traumatic brain injury. *Journal of Neuroinflammation* 2017; 14(1): pp. 1–17. doi: 10.1186/s12974-016-0786-1.
22. Zollman, Felise S. *Manual of traumatic brain injury: assessment and management*. 2nd ed. New York, NY : Demos Medical Publishing; 2016. pp. 369-71. ISBN 9781620700938
23. McBride DW. et al. Reduction of cerebral edema after traumatic brain injury using an osmotic transport device. *Journal of Neurotrauma* 2014; 31(23): 1948–54. doi: 10.1089/neu.2014.3439.
24. Bosoi CR, Rose CF. Brain edema in acute liver failure and chronic liver disease: Similarities and differences. *Neurochem. Int* 2013; 62: 446–57.

25. Wright G, Sharifi Y, Jover-Cobos, M, Jalan, R. The brain in acute on chronic liver failure. *Metab. Brain Dis* 2014; 4: 965–73.
26. Kahle KT, Simard JM, Staley KJ, Nahed BV, Jones PS, Sun D. Molecular mechanisms of ischemic cerebral edema: Role of electroneutral ion transport. *Physiology (Bethesda)* 2009; 24: 257–65.
27. Rabinstein AA. Treatment of brain edema in acute liver failure. *Curr. Treat. Opt. Neurol* 2010; 2: 129–41.
28. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. *Biochim. Biophys. Acta* 2009; 4: 842–57.
29. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc. Natl. Acad. Sci. USA* 2009; 6: 977–82.
30. Jha, RM., Kochanek, PM., Simard, JM,. Pathophysiology and treatment of cerebral edema in traumatic brain injury. *Neuropharmacology* 2019; 145: 230–46
31. Aliah A, Widjaja D. Edema Cerebri, pendekatan patogenetik dan terapeutik. Makassar: Laboratorium Saraf FK UH 2006:1-19
32. Grossetete M. et al. 'Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury', *Neurosurgery* 2009; 65(4): 702-8. doi: 10.1227/01.neu.0000351768.11363.48.

33. Faló MC, Fillmore HL, Reeves TM, Phillips LL. Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. *J. Neurosci. Res* 2006; 84: 768–81.
34. Gidday JM. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. *American Journal of Physiology-Heart and Circulatory Physiology* 2005; 289(2): H558–68. doi: 10.1152/ajpheart.01275.2004.
35. Vajtr D. et al. Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after TBI with biochemical markers of blood brain barrier leakage and inflammatory response. *Physiological Research* 2009; 58(2): pp. 263–8.
36. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. *Nat Rev Neurosci* 2005; 6:931–44.
37. Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang Y, Chopp M. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. *J Neurosci* 2009; 26:5996–6003.
38. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. *Glia* 2005; 50:329–39.

39. Liu KJ, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. *Free Radic Biol Med* 2005; 39: 71–80.
40. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. *Glia* 2002; 39: 279–91.
41. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. *J Cereb Blood Flow Metab* 2007; 27:697–709.
42. Rosenberg GA, Taheri S, Jalil EC. Brain Edema in Neurological Diseases; Neurochemical Mechanisms in Disease, Neurobiology. London. Springer Science Business Media. 2011: pp.125-56. doi: 10.1007/978-1-4419-7104-3.
43. Yang Z, Fan R, Sun P, Cui H, Peng W. Rhubarb attenuates cerebral edema via inhibition of the extracellular signal-regulated kinase pathway following traumatic brain injury in rats. *Phcog Mag* 2018;14:134-9.
44. Ding JY, Kreipke CW, Schafer P, Schafer S, Speirs SL Synapse Loss Regulated by Matrix Metalloproteinases in Traumatic brain injury Is Associated with Hypoxia-Inducible Factor-1 α Expression. *Brain Res* 2009; May 1; 1268: 125–34.

45. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. *Lancet Neurol*. 2004 Dec;3(12):744-51. DOI: 10.1016/S1474-4422(04)00937-8
46. Jennifer MP, Yan S, David EP. Prospects for Minocycline Neuroprotection. *Arch Neurol*. 2010;67(12):1442-1448. Published online August 9, 2010. doi:10.1001/archneurol.2010.191
47. Chang JJ, Tenser MK, Emanuel BA. Minocycline and Matrix Metalloproteinase Inhibition in Acute Intracerebral Hemorrhage: a Pilot study. *European Journal of Neurology* 2017, 0:1-8. doi:10.1111/ene.13403
48. Mesa NG, Zarzuelo A. and Gálvez J. Minocycline: Far Beyond an Antibiotic. *Br J Pharmacol*. 2013 May;169(2):337-52. doi: 10.1111/bph.12139.
49. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *J Antimicrob Chemother* 2006; 58:256–65.
50. Ritchie DJ, Wilson AG. A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant *Acinetobacter* Infections. *Clinical Infectious Diseases*, Volume 59, Issue suppl_6, December 2014, Pages S374–S380, <https://doi.org/10.1093/cid/ciu613>
51. Fouda AY, Newsome AS. Minocycline in Acute Cerebral Hemorrhage, An Early Phase Randomized Trial.

52. Roeland RH, Lent NV, Sorsa T, Salo T, Yrjö Lindeman J. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines. *Tetracyclines in Biology, Chemistry and Medicine*. 2001. London: Springer. pp 267-81
53. Raz L, Yang Y, Thompson J. MMP-9 inhibitors impair learning in spontaneously hypertensive rats. RESEARCH ARTICLE. Published: December 11, 2018. <https://doi.org/10.1371/journal.pone.0208357>
54. Lee CZ, Yao JZ, Huang Y. Dose–Response Effect of Tetracyclines on Cerebral Matrix Metalloproteinase-9 after Vascular Endothelial Growth Factor Hyperstimulation. *Sage Journal*. September 1, 2006. <https://doi.org/10.1038/sj.jcbfm.9600268>
55. Xu L, Fagan SC, Waller JL, Edwards D. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. *BMC Neurol*. 2004 Apr 26;4:7. DOI:10.1186/1471-2377-4-7
56. Pyo R, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. *J Clin Invest*. 2000;105: 1641–9.

57. Zhang C, Gong W, Ge S. Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass *Int J Clin Exp Med*. 2014; 7(12): 4975–82.
58. Leung LY, et al. Blast related neurotrauma: a review of cellular injury. *Mol Cell Biomech*. 2008; 5:155–168. [PubMed: 18751525]
59. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. *J Neurosci Methods*. 1991; 39:253–262. [PubMed: 1787745]